Verastem Oncology develops and commercializes oncology medicines for RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK in the U.S. for KRAS-mutated recurrent low-grade serous ovarian cancer and reports commercial updates, product revenue, and medical-conference data for the avutometinib and defactinib combination.
Recurring VSTM news also covers the company’s small-molecule pipeline, including RAF/MEK inhibition, FAK inhibition, and VS-7375, an oral KRAS G12D inhibitor studied in KRAS G12D-mutant solid tumors. Company updates commonly include clinical-trial analyses from RAMP studies, preclinical research presentations, FDA-related treatment context, patient advocacy resources for LGSOC, executive and employee equity grants, and quarterly financial results.
Verastem Oncology (VSTM) will discuss its third quarter 2026 financial results and business updates on November 5, 2026. The conference call and webcast will begin at 4:30 pm ET. Live audio and accompanying slides will be available in the website's Investor section under Events & Presentations, with a webcast replay available afterward.
Verastem Oncology (Nasdaq: VSTM) priced an underwritten offering expected to generate approximately $250 million in gross proceeds from company-issued securities. The offering comprises 30,937,500 common shares at $8.00 per share and, in lieu of common stock for certain investors, pre-funded warrants to purchase up to 312,503 common shares. Each warrant costs $7.9999 and carries a $0.0001 per-share exercise price.
Gross proceeds exclude underwriting discounts, commissions and estimated offering expenses payable by Verastem. The company expects closing on or about October 15, 2026, subject to customary closing conditions, and intends to use net proceeds for continued clinical development of product candidates, including VS-7375, plus working capital and other general corporate purposes. Jefferies, Guggenheim Securities and Cantor are joint book-running managers; B. Riley Securities is lead manager.
Verastem Oncology (VSTM) appointed Michael P. Bailey as President and Chief Executive Officer, effective January 1, 2027, under its succession plan. Daniel Paterson will retire from those roles and remain a director and company advisor. Bailey will also continue serving on the board, which he joined in May 2026.
The transition follows Paterson’s 15 years at Verastem, including leadership of the acquisition and commercialization of AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer. The investigational oral KRAS G12D inhibitor VS-7375 has advanced to Phase 2 trials across multiple tumor types. Verastem expects a Phase 3 trial in first-line metastatic pancreatic cancer to begin later in 2026. Bailey’s responsibilities will include advancing the commercial business and development pipeline.
Verastem Oncology (VSTM) reported a 50% confirmed response rate for VS-7375 in second-line pancreatic cancer in its ongoing Phase 1/2 trial. At 900 mg once daily, four of eight patients responded; the confirmed response rate across second-line and later pancreatic cancer was 41% (9/22). Two complete responses occurred, one confirmed and one unconfirmed. Six-month progression-free survival, meaning survival without disease worsening, was 67%.
Colorectal cancer patients receiving 900 mg with anti-EGFR therapy had a 33% response rate (2/6), with one response confirmed. Lung cancer patients receiving 600 mg alone had a 43% confirmed response rate (10/23). At 900 mg alone, adverse events caused 2% to discontinue, and Grade 3 treatment-related events occurred in 10%. FDA alignment was reached on the first-line pancreatic cancer Phase 3 design; Verastem plans to open the trial by year-end 2026.
Verastem Oncology (VSTM) granted 380,500 restricted stock units to new employees as inducements to accept employment with the company.
The restricted stock units, which are awards of company shares subject to vesting, went to 24 new employees. One new employee received options to purchase 50,000 common shares at an exercise price of $7.90. The awards use the Nasdaq inducement grant exception under Listing Rule 5635(c)(4).
Both award types vest 25% on each employee’s first hiring anniversary, with the remainder vesting in equal quarterly amounts over the next three years. Vesting requires continued employment or other service on each vesting date.
Verastem Oncology (VSTM) announced new Phase 2 analyses of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer.
In RAMP 201, confirmed objective response rates, measuring tumor responses, were 18% (7/39) in KRAS/NRAS/BRAF triple wild-type tumors and 22% (2/9) in KRAS wild-type tumors with NRAS or BRAF mutations. Median progression-free survival, time without disease worsening, was 13 months in the triple wild-type group.
A matched, reweighted external comparison with conventional care found weighted response rates of 38.7% versus 0% in KRAS-mutated disease and 22.7% versus 7.9% in KRAS wild-type disease. Median weighted progression-free survival was 22.1 versus 6.5 months and 11.3 versus 7.7 months, respectively. Both survival comparisons were statistically significant. An encore Japanese Phase 2 analysis reported a 44% response rate among 16 efficacy-evaluable patients.
Verastem Oncology (VSTM) announced publication of two-year follow-up findings from its Phase 2 RAMP 201 ovarian cancer study.
In the 17-patient long-term analysis, median duration of response was 31.1 months and median progression-free survival was 12.9 months, both unchanged from the 109-patient primary analysis. Among patients with KRAS wild-type disease, median response duration rose to 12 months from 9.2 months. For KRAS-mutated disease, median progression-free survival was 19.6 months, down from 22 months. No new safety signals were observed, and 12% of patients discontinued treatment because of adverse events.
The combination has U.S. accelerated approval for adults with previously treated KRAS-mutated recurrent low-grade serous ovarian cancer. Continued approval may depend on confirmation of clinical benefit in a Phase 3 trial.
Verastem Oncology (VSTM) will present RAMP 201 molecular profiling and tumor biomarker analysis at the IGCS meeting on October 2, 2026.
The late-breaking oral presentation concerns its Phase 2 trial of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer. Previously reported results from the RAMP 201J study in Japanese patients will also receive an oral presentation. An external-control comparison with conventional care is scheduled for poster rounds.
Verastem Oncology (VSTM) will host an investor event and webcast on October 14, 2026, at 8:00 am ET to present initial efficacy and updated safety and tolerability data for VS-7375 in pancreatic, lung, and colorectal cancers from the ongoing TARGET-D clinical development program.
The presentation will provide the first broader safety and efficacy assessment of VS-7375 across these tumor types and follows a clinical update reported in June 2026. VS-7375 is described as an investigational, potent and selective, oral KRAS G12D dual ON/OFF inhibitor designed to bind both active and inactive KRAS G12D states. Verastem is evaluating VS-7375 in the Phase 1/2 TARGET-D 101 trial and three registration-directed Phase 2 studies: TARGET-D 201 in metastatic pancreatic ductal adenocarcinoma, TARGET-D 202 in advanced non-small cell lung cancer, and TARGET-D 203 in metastatic colorectal cancer.
VS-7375 has FDA Fast Track Designations in KRAS G12D-mutated locally advanced or metastatic PDAC and previously treated unresectable locally advanced or metastatic NSCLC.
Verastem Oncology (VSTM)/b) will participate in multiple September 2026 healthcare investor conferences, including Wells Fargo, Cantor, and H.C. Wainwright events.Management will join the Wells Fargo 21st Annual Healthcare Conference on September 8 in Boston, then present at the Cantor Global Healthcare Conference on September 10 and the H.C. Wainwright Annual Global Investment Conference on September 14, both in New York City. Live and archived webcasts of these fireside chats will be available for approximately 90 days on the company’s website under “Events & Presentations.”